covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Historial de cribado oportunista mediante citología cervical en 277 casos de ca...
Journal Information
Vol. 47. Issue 5.
Pages 214-221 (January 2004)
Share
Share
Download PDF
More article options
Vol. 47. Issue 5.
Pages 214-221 (January 2004)
Full text access
Historial de cribado oportunista mediante citología cervical en 277 casos de carcinoma escamoso in situ/invasivo de cérvix
Cervical cytology screening histories of 277 cases of in situ/invasive squamous cervical carcinoma
Visits
3443
P. Castroa,
Corresponding author
patologia@htrueta.scs.es

Correspondencia: Servei d’Anatomia Patològica. Hospital Universitari de Girona Doctor Josep Trueta. Av. de França s/n. 17007 Girona. España
, R. Marcosb, E. Lópeza, J. Sabriác, A. Izquierdob, C. Barcelóa
a Servei d’Anatomia Patològica. Hospital Universitari de Girona Doctor Josep Trueta. Institut Català de la Salut. Girona
b Unitat d’Epidemiologia i Registre de Càncer a Girona. Institut Català d’Oncologia. Servei Català de la Salut. Girona
c Servei d’Obstetrícia i Ginecologia. Hospital Universitari de Girona Doctor Josep Trueta. Institut Català de la Salut. Girona. España
This item has received
Article information
Resumen
Objetivo

Análisis del historial de cribado oportunista en 277 casos de carcinoma escamoso de cérvix (in situ = 221, invasivo = 56).

Material y métodos

Criterios de inclusión: diagnóstico histológico de carcinoma y una citología cervical hasta 5 años antes. Se utiliza la terminología “The 2001 Bethesda System”.

Resultados

La proporción de carcinoma in situ/invasivo es 4:1 (10:1 en 2002). La media de edad es 42,7 años (17-84): in situ, 40,3 (17-84); microinvasivo, 45,6 (30-68); invasivo, 53,4 (31-84); (F = 24,3; p < 0,0001). Hay 1,8 citologías por caso (rango, 1-6). La mediana del intervalo de diagnostico es 1 mes (rango, 1-66). La citología previa al diagnóstico es positiva en un 78,8%; LSIL (low grade squamous intraepithelial lesion), 10,7%; ASC-H (atipical squamous cells cannot exclude HSIL), 5,9%; ASC-US (atipical squamous cells of undetermined significance), 1,9%, y negativa, 0,8%. La citología (5 años previos) es positiva en un 43,6%, LSIL 16,6%, ASC-H 3,8%, ASCUS 14,2% y negativa 21,8%. En la revisión, la citología negativa (109), sigue siendo negativa en un 56,8%, es inadecuada para el 33,9% y es positiva para el 9,1%.

Conclusiones

El estudio sugiere la necesidad de un cribado organizado.

Palabras clave:
Cribado
Citología
Cáncer de cérvix
Abstract
Objective

To analyze the histories of opportunistic screening in 277 cases of cervical squamous carcinoma (in situ = 221, invasive = 56).

Material and methods

Inclusion criteria consisted of biopsy-proven diagnosis and cytology up to 5 years previously. The cytology results were expressed according to “The 2001 Bethesda System”.

Results

The ratio in situ/invasive carcinoma was 4:1 (10:1 in 2002). The mean age was 42.7 years (17-84): in situ, 40.3 (17-84); microinvasive, 45.6 (30-68); invasive, 53.4 (31-84); (F=24.3; P<.0001). There were 1.8 (range: 1-6) cytology smears per case. The median diagnostic interval was 1 month (range: 1-66). Cytology prior to diagnosis was positive in 78.8%, low-grade squamous intraepithelial lesion (LSIL) in 10.7%, atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H) in 5.9%, ASC of undetermined significance (ASC-US) in 1.9% and was negative in 0.8%. Cytology (in the 5 previous years) was positive in 43.6%, LSIL in 16.6%, ASC-H in 3.8%, ASC-US in 14.2% and was negative in 21.8%. After review of 109 negative smears, 56.8% remained negative, 33.9% were inadequate and 9.1% were positive.

Conclusions

The results of this study strongly suggest the need for organized screening.

Keywords:
Screening
Cytology
Cervical cancer
Full text is only aviable in PDF
Bibliografía
[1.]
D.M. Eddy.
Screening for cervical cancer.
Ann Intern Med, 113 (1990), pp. 214-226
[2.]
IARC Working group on evaluation of cervical cancer screening programmes.
Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies.
Br Med J, 293 (1986), pp. 659-664
[3.]
M.T. Fahey, L. Irwig, P. Macastill.
Meta-analysis of Pap test accuracy.
Am J Epidemiol, 141 (1995), pp. 680-689
[4.]
K. Nanda, D.C. MacCrory, E.R. Myers, L.A. Bastian, V. Hasselblad, J.D. Hickey, et al.
Accuracy of the Papanicolaou test screening for and follow-up of cervical abnormalities: a systematic review.
Ann Intern Med, 132 (2000), pp. 810-819
[5.]
B.A. Jones.
Rescreening in gynecologic cytology. Rescreening of 3762 previous cases for current high-grade squamous intraepithelial lesions and carcinoma. A College of American Pathologists Q-Probes study of 312 institutions.
Arch Pathol Laboratory Med, 119 (1995), pp. 1097-1103
[6.]
M.L. Hutchinson, D.J. Zahniser, M.E. Sherman, et al.
Utility of liquid- based cytology for cervical carcinoma screening: results of a population based study conducted in a region of Costa Rica with high incidence of cervical carcinoma.
Cancer, 87 (1999), pp. 48-55
[7.]
American College of Obstetricians and Gynecologist Committee opinion.
New PAP test screening techniques.
Int J Gynecol Obstet, 63 (1998), pp. 312-314
[8.]
G.F. Sawaya, A.E. Washington.
Cervical cancer screening: which techniques should be used and why.
Clin Obstet Gynecol, 42 (1999), pp. 922-938
[9.]
Cervical Cancer, American Cancer Society. Disponible en: http://www.cancer.org
[10.]
G.F. Sawaya, K.J. McConnell, S.L. Kulasingam, H.W. Lawson, K. Kerlikowske, J. Melnikow, et al.
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings.
N Engl J Med, 349 (2003), pp. 1501-1509
[11.]
A.B. Miller, J. Lindsay, G.B. Hill.
Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix.
Int J Cancer, 17 (1976), pp. 602-612
[12.]
Cancer incidence in five continents Vol.VIII,
[13.]
M.T. Fernández, A. Hernández, I. Rosell.
Cervical cancer screening in Spain.
Eur J Cancer, 6 (2000), pp. 2250-2254
[14.]
P. Viladiu, A. Izquierdo, R. Marcos, L. Vilardell, F.X. Bosch, V. Moreno, et al.
El Càncer a Girona 1994-1997.Unitat d’Epidemiologia i Registre de Càncer a Girona. Institut d’Assistència Sanitària.
pp. 93-96
[15.]
D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O’Connor, M. Prey, et al.
The 2001 Bethesda System. Terminology for reporting results of cervical cytology.
Jama, 287 (2002), pp. 2114-2119
[16.]
L.A. Sheils, D.C. Wilbur.
Atypical squamous cells of undetermined significance. Stratification of the risk of association with, or progression to, squamous intraepithelial lesions based on morphologic sub categorisation.
Acta Cytol, 41 (1997), pp. 1065-1071
[17.]
W.K. Kinney, M.M. Manos, L.B. Hurtley, J.E. Ransley.
Where’s the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses.
Obstet Gynecol, 91 (1998), pp. 973-976
[18.]
T.C. Wright, J.T. Cox, L.S. Massad, L.B. Twiggs, E.J. Wilkinson.
2001 consensus guidelines for the management of women with cervical cytological abnormalities.
J Lower Gen Tract Dis, 6 (2002), pp. 127-143
[19.]
D.T. Janerich, D. Hadjimichael, P.E. Schwartz, D.M. Lowel, J.W. Meigs, M.J. Merino, et al.
The screening histories of women with invasive cervical cancer, Connecticut.
Am J Public Health, 85 (1995), pp. 791-794
[20.]
C. Bergeron, H. Debaque, J. Ayivi, S. Amaizo, F. Fagnani.
Cervical smear histories of 585 women with biopsy-proven carcinoma in situ.
Acta Cytol, 41 (1997), pp. 1676-1680
[21.]
C.M. Anderson, J. Nottingham.
Bridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology; we need unbiased information and a culture change.
Cytopathology, 10 (1999), pp. 221-228
[22.]
Cancer of the cervix: death by incompetence [editorial]..
Lancet, ii (1985), pp. 363-364
[23.]
L.G. Koss.
The Papanicolaou test for cervical detection. A triumph and a tragedy.
Jama, 261 (1989), pp. 737-743
[24.]
Cervical cancer screening: the Pap smear.
Summary of a NIH consensus statement.
Br Med J, 281 (1980), pp. 1264-1266
[25.]
P. Castro Marqueta.
Infección por papiloma virus y cáncer de cérvix.
Med Clin (Barc), 96 (1991), pp. 631-634
[26.]
F.X. Bosch, A. Lorincz, M. Muñoz, C.J.L. Meijer, K.V. Shah.
The causal relation between human papilloma virus and cervical cancer.
J Clin Pathol, 55 (2002), pp. 244-265
[27.]
J. Cuzick, E. Beverley, L. Ho, G. Terry, H. Sapper, Mielzynska, et al.
HPV testing in primary screening of older women.
Br J Cancer, 81 (1999), pp. 554-558
[28.]
D. Solomon, M. Schiffman, R. Tarone.
Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.
J Natl Cancer Inst, 93 (2001), pp. 293-299
[29.]
C.B. Woodman, S. Collins, H. Winter, A. Bailey, J. Ellis, P. Prior, et al.
Natural history of cervical human papilloma-virus infection in young women: a longitudinal cohort study.
Lancet, 357 (2001), pp. 1831-1836
[30.]
J. Tidy.
Forgotten implications of HPV positivity for the majority of females: a clinical perspective.
Cytopathology, 13 (2002), pp. 263-266
[31.]
T.C. Wright, M. Schiffman.
Adding a test for human papillomavirus DNA to cervical-cancer screening.
N Engl J Med, 348 (2003), pp. 489-490
[32.]
N. Roach.
Delivering human papilloma virus testing to the public. One patient advocate’s perspective.
Arch Pathol Lab Med, 127 (2003), pp. 995-996
[33.]
D.A. Grimes, K.F. Schulz.
Uses and abuses of screening test.
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos